M. Taalikka

Irritable bowel syndrome symptom severity improves equally with probiotic and placebo

A. Lyra, M. Hillilä, T. Huttunen, 2016, World journal of gastroenterology.

Outcome of Burch Retropubic Urethropexy and the Effect of Concomitant Abdominal Hysterectomy: A Prospective Long-term Follow-up Study

M. Taalikka, J. Mäkinen, P. Kiilholma, 2001, International Urogynecology Journal.

Hysterectomy for gynaecological cancer: A follow‐up study of subjective and objective outcome

S. Hietanen, M. Taalikka, J. Mäkinen, 2004, The Australian & New Zealand journal of obstetrics & gynaecology.

One-year cohort of abdominal, vaginal, and laparoscopic hysterectomies: complications and subjective outcomes.

H. Helenius, M. Taalikka, J. Mäkinen, 1999, Journal of the American College of Surgeons.

Complications and long-term outcomes after adnexal surgery by laparotomy and laparoscopy.

H. Helenius, M. Taalikka, J. Mäkinen, 1999, The Journal of the American Association of Gynecologic Laparoscopists.

Incidence, risk factors and outcome of infection in a 1-year hysterectomy cohort: a prospective follow-up study.

H. Helenius, M. Taalikka, J. Mäkinen, 2000, The Journal of hospital infection.

Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men.

R. Huupponen, H. Scheinin, E. Salminen, 2001, British journal of clinical pharmacology.

High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: A preplanned safety report of SPCG 13 trial.

P. Kellokumpu-Lehtinen, M. Taalikka, C. Thellenberg-Karlsson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

P. Kellokumpu-Lehtinen, M. Taalikka, C. Thellenberg-Karlsson, 2012, Prostate Cancer and Prostatic Diseases.

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

J. Mohler, P. Kellokumpu-Lehtinen, M. Taalikka, 2012, Prostate Cancer and Prostatic Diseases.